Q-omics provides the consensus-scored MT1L profile across patient tissues and cancer cell-line models. MT1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, MT1L is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, MT1L RNA expression shows 13,746 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRP, and LSCC as cancer lineages where MT1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1L survival associations across molecular data types. MT1L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1L RNA expression–survival associations across cancer types. High MT1L expression shows unfavorable associations in LUSC, PAAD, CESC, LGG and UCS, but favorable associations in UCEC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for MT1L RNA expression.
This table summarizes MT1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MT1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1L shows lower tumor expression in KIRP, THCA, BLCA, LIHC, COAD and LUSC. The KIRP box plot shows higher MT1L RNA expression in normal versus tumor tissue (log2 FC = −3.432, t-test p < 0.001).
This table shows molecular features associated with MT1L in patient tissues and cancer cell lines. In patient samples, MT1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma.
